115 related articles for article (PubMed ID: 34297482)
21. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
22. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.
Paskaš S; Janković J; Živaljević V; Tatić S; Božić V; Nikolić A; Radojković D; Savin S; Cvejić D
Cancer Cytopathol; 2015 Aug; 123(8):471-9. PubMed ID: 25924719
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules.
Trimboli P; Guidobaldi L; Amendola S; Nasrollah N; Romanelli F; Attanasio D; Ramacciato G; Saggiorato E; Valabrega S; Crescenzi A
Endocrine; 2016 Apr; 52(1):39-45. PubMed ID: 26142180
[TBL] [Abstract][Full Text] [Related]
25. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
Straccia P; Rossi ED; Bizzarro T; Brunelli C; Cianfrini F; Damiani D; Fadda G
Cancer Cytopathol; 2015 Dec; 123(12):713-22. PubMed ID: 26355876
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples.
Collet JF; Hurbain I; Prengel C; Utzmann O; Scetbon F; Bernaudin JF; Fajac A
Br J Cancer; 2005 Nov; 93(10):1175-81. PubMed ID: 16251880
[TBL] [Abstract][Full Text] [Related]
27. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules.
Hooft L; van der Veldt AA; Hoekstra OS; Boers M; Molthoff CF; van Diest PJ
Clin Endocrinol (Oxf); 2008 Feb; 68(2):252-7. PubMed ID: 17868400
[TBL] [Abstract][Full Text] [Related]
28. Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR.
Samija I; Mateša N; Lukač J; Kusić Z
Diagn Mol Pathol; 2011 Dec; 20(4):233-41. PubMed ID: 22089351
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
30. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
31. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
33. [Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules].
Wang LH; Zhao YJ; Wang XY; Yuan P; Xu WQ; Xiao JC; Xu JP; Luo BR
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):547-50. PubMed ID: 16438854
[TBL] [Abstract][Full Text] [Related]
34. Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
Arcolia V; Journe F; Wattier A; Leteurtre E; Renaud F; Gabius HJ; Remmelink M; Decaestecker C; Rodriguez A; Boutry S; Laurent S; Saussez S
Int J Oncol; 2017 Sep; 51(3):760-770. PubMed ID: 28677745
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
[TBL] [Abstract][Full Text] [Related]
36. [Detection of galectin-3 in both serum and tissue for early diagnosis of thyroid carcinoma].
Xue G; Liu J; Huang J; Zhang J; Zhang W; Wu J; Shang X
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1027-30. PubMed ID: 23895846
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
39. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories.
Onder S; Firat P; Ates D
Cytopathology; 2014 Jun; 25(3):177-84. PubMed ID: 23998291
[TBL] [Abstract][Full Text] [Related]
40. A histological assessment of the Bethesda system for reporting thyroid cytopathology (2010) abnormal categories: a series of 219 consecutive cases.
Tepeoğlu M; Bilezikçi B; Bayraktar SG
Cytopathology; 2014 Feb; 25(1):39-44. PubMed ID: 23438201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
